Cargando…

CNOT4 enhances the efficacy of anti‐PD‐1 immunotherapy in a model of non‐small cell lung cancer

The use of immune checkpoint inhibitors that target programmed cell death‐1 (PD‐1) has been proposed for the treatment of advanced non‐small cell lung cancer (NSCLC). However, in clinical trials, cumulative response rates to anti‐PD‐1 treatment were approximately 20% in patients with NSCLC. CCR4‐NOT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Biao, Han, Song, Ma, Haitao, Chen, Shaomu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714061/ https://www.ncbi.nlm.nih.gov/pubmed/33034149 http://dx.doi.org/10.1002/2211-5463.12998

Ejemplares similares

The human CNOT1-CNOT10-CNOT11 complex forms a structural platform for protein-protein interactions
por: Mauxion, Fabienne, et al.
Publicado: (2022)

Enhanced recovery after surgery using uniportal video‐assisted thoracic surgery for lung cancer: A preliminary study
por: Huang, Haitao, et al.
Publicado: (2017)

CNOT2 Is Critically Involved in Atorvastatin Induced Apoptotic and Autophagic Cell Death in Non-Small Cell Lung Cancers
por: Lee, Jihyun, et al.
Publicado: (2019)

Targeting the up-regulated CNOT3 reverses therapeutic resistance and metastatic progression of EGFR-mutant non-small cell lung cancer
por: Jing, Lin, et al.
Publicado: (2023)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
por: Dantoing, Edouard, et al.
Publicado: (2021)

Fascaplysin Induces Apoptosis and Ferroptosis, and Enhances Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) by Promoting PD-L1 Expression
por: Luo, Lianxiang, et al.
Publicado: (2022)

The Anti-Proliferative Activity of BTG/TOB Proteins Is Mediated via the Caf1a (CNOT7) and Caf1b (CNOT8) Deadenylase Subunits of the Ccr4-Not Complex
por: Doidge, Rachel, et al.
Publicado: (2012)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
por: Zhang, Yaxiong, et al.
Publicado: (2018)

Alternative splicing of CNOT7 diversifies CCR4–NOT functions
por: Chapat, Clément, et al.
Publicado: (2017)

CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer
por: Olingy, Claire, et al.
Publicado: (2022)

FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer
por: Liu, Jiaxin, et al.
Publicado: (2022)

Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
por: Jin, Runsen, et al.
Publicado: (2020)

Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer
por: Cui, Pengfei, et al.
Publicado: (2020)

PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
por: Luo, Min, et al.
Publicado: (2021)

A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer
por: You, Wei, et al.
Publicado: (2018)

Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer
por: Nishioka, Naoya, et al.
Publicado: (2019)

Role of Cnot6l in maternal mRNA turnover
por: Horvat, Filip, et al.
Publicado: (2018)

The role of seven autoantibodies in lung cancer diagnosis
por: Luo, Bin, et al.
Publicado: (2021)

CNOT6: A Novel Regulator of DNA Mismatch Repair
por: Song, Peng, et al.
Publicado: (2022)

The Ccr4a (CNOT6) and Ccr4b (CNOT6L) deadenylase subunits of the human Ccr4–Not complex contribute to the prevention of cell death and senescence
por: Mittal, Saloni, et al.
Publicado: (2011)

Cnot3 enhances human embryonic cardiomyocyte proliferation by promoting cell cycle inhibitor mRNA degradation
por: Zhou, Bingying, et al.
Publicado: (2017)

Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy
por: Zeng, Xianghua, et al.
Publicado: (2020)

T Cell Invigoration is Associated with the Clinical Response to Anti-PD-1-Based Immunotherapy in Non-Small Cell Lung Cancer
por: Wu, Hui, et al.
Publicado: (2023)

RPB5-mediating protein promotes the progression of non-small cell lung cancer by regulating the proliferation and invasion
por: Feng, Yu, et al.
Publicado: (2021)

Lung Cancer Surgery after Treatment with Anti-PD1/PD-L1 Immunotherapy for Non-Small-Cell Lung Cancer: A Case—Cohort Study
por: El Husseini, Kinan, et al.
Publicado: (2021)

Granzyme B for predicting the durable clinical benefit of anti-PD-1/PD-L1 immunotherapy in patients with non-small cell lung cancer
por: Chung, Jae Heun, et al.
Publicado: (2022)

Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer
por: Hwang, Sohyun, et al.
Publicado: (2020)

Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer
por: Ghiringhelli, François, et al.
Publicado: (2023)

An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
por: Cowles, Sarah C., et al.
Publicado: (2022)

Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota
por: He, Daqiang, et al.
Publicado: (2021)

BATF acts as an oncogene in non-small cell lung cancer
por: Feng, Yu, et al.
Publicado: (2020)

Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST
por: Goldfarb, Lucas, et al.
Publicado: (2019)

Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer
por: Li, Yanping, et al.
Publicado: (2023)

MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer
por: Lecuelle, Julie, et al.
Publicado: (2022)

CNOT4-Mediated Ubiquitination of Influenza A Virus Nucleoprotein Promotes Viral RNA Replication
por: Lin, Yu-Chen, et al.
Publicado: (2017)

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
por: Banna, Giuseppe Luigi, et al.
Publicado: (2020)

Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non–Small Cell Lung Cancer
por: Li, Jia-Xin, et al.
Publicado: (2019)

Anti‐PD1 versus anti‐PD‐L1 immunotherapy in first‐line therapy for advanced non‐small cell lung cancer: A systematic review and meta‐analysis
por: Brito, Angelo Borsarelli Carvalho, et al.
Publicado: (2021)

Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer
por: Luo, Min, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l0hlk1n0o7bj296ddbhcdc1mft